This page grades the evidence and stops there: no recommendation, no dosing, no reconstitution detail.

01 Identity

Common name	BPC-157
Meaning	"Body Protection Compound 157"
Class	Synthetic pentadecapeptide (15 amino acids)
Sequence	Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Reported origin	Described by its originating group as a partial sequence of a "body protection compound" from human gastric juice
CAS number	137525-51-0 · PubChem CID 9941957 · confirmed (salt forms differ)

Reported stable in gastric juice (rationale for oral animal dosing). The claim that it is a natural fragment of an endogenous compound originates substantially from the group that first described it; best treated as their characterisation rather than independently settled fact.

02 Regulatory status

BPC-157 holds no marketing authorisation anywhere and is not approved by the FDA, EMA, or MHRA for any indication.

The FDA placed BPC-157 among substances raising concerns for pharmacy compounding (2023 review). The World Anti-Doping Agency prohibits it at all times (class S0, non-approved substances). It is otherwise sold as a "research chemical," frequently as the arginate salt. No controlled-substance scheduling. Confirm specifics against FDA and WADA documents.

03 Mechanism of action

Proposed mechanisms (animal and in-vitro) include promotion of angiogenesis, modulation of the nitric-oxide system, effects on growth-factor and growth-hormone-receptor expression in fibroblasts, and cytoprotection of the gut and other tissues, with reported effects across tendon, ligament, muscle, bone, nerve, gut, and blood vessels.

The mechanistic literature is broad but diffuse, with many proposed pathways and no single established mode of action, and it is concentrated in one research lineage. A wide range of claimed effects with an unclear unifying mechanism is a reason for caution, not confidence.

04 Pharmacokinetics / pharmacodynamics

Human pharmacokinetics are essentially uncharacterised. One small human study examined intravenous safety/pharmacokinetics; otherwise absorption, half-life, and systemic exposure in humans, including for the oral and subcutaneous routes used in the community, are not established.

05 Evidence by endpoint

A large preclinical literature concentrated in a single research group, against a very thin human record.

5.1 — Musculoskeletal soft-tissue healing (tendon, ligament, muscle) — the popular use

The use BPC-157 is sought for, and the human evidence for it is absent. Supporting data are animal studies — transected rat Achilles tendon, MCL injury, quadriceps transection — reporting improved biomechanical strength and collagen organisation, plus in-vitro fibroblast outgrowth. No randomised controlled human trials; human reports are case series and anecdote.

Preclinical only

5.2 — Gastrointestinal protection / IBD

The originating work was gastrointestinal. An oral analogue (developed as PL 14736) reportedly entered Phase 2 for inflammatory bowel disease years ago, without progressing to approval.

Preclinical (inconclusive early-phase)

5.3 — Other reported uses (neuro, vascular, organ protection)

Reported across many animal models.

Preclinical / mechanistic

5.4 — What human data actually exist

A recent narrative review identified only about three small human pilot studies — intra-articular knee pain, interstitial cystitis, and an IV safety/PK study. Small and preliminary; they do not establish efficacy for any indication, least of all the musculoskeletal uses.

Pilot only — not efficacy-establishing

Methodological caveat. The great majority of BPC-157's preclinical literature originates from one research group and its collaborators; independent replication is limited. A large publication count from a narrow source is not the same as a broadly replicated finding — volume of papers should not be mistaken for strength of evidence.

06 Safety and adverse events

There is no robust human safety dataset. A single small IV study examined short-term safety/PK; otherwise human safety is uncharacterised, with no long-term data. Animal studies report a wide safety margin, but animal tolerability does not establish human safety.

Product-quality risks apply independently of the molecule: research-chemical material (including the common arginate salt) varies in identity, purity, and sterility — relevant for any injected use. BPC-157 is prohibited in sport at all times (WADA S0).

07 Evidence summary

Endpoint	Grade
Musculoskeletal healing	Preclinical only
Gastrointestinal / IBD	Preclinical
Neuro / vascular / organ	Preclinical / mechanistic
Human efficacy (any)	Pilot only
Human safety	Largely uncharacterised

08 References

Chang C-H, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing... J Appl Physiol. 2011;110(3):774–780.PubMed 21030672
Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21:976–983.
Chang C-H, et al. Pentadecapeptide BPC 157 enhances growth-hormone-receptor expression in tendon fibroblasts.PMC6271067
Seiwerth S, Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533.Review — note single-group authorship
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing.PMC12446177 — states human data extremely limited (~3 pilots)
FDA — 2023 bulk drug substances review (compounding). · WADA — Prohibited List, class S0.Cite documents directly